Figure 4
Figure 4. Engraftment of CD34+CLL-1+ AML blasts in NOD/SCID mice. FACS-sorted CD34+CLL-1+ cells from 3 different AML patients were transplanted into NOD/SCID mice. Six weeks after transplantation, the mice were killed and engraftment of human cells in these mice was studied using human anti-CD45. In this figure, the overall results are depicted on a logarithmic scale; every symbol represents the percentage engraftment of human CD45+ cells in one mouse. In a mouse that received a transplant of the whole CD34+ population from patient 2, which included the CD34+CD38−CLL+, but also a clear CD34+CD38−CLL-1− population (15% of the CD34+CD38− population), outgrowth of CD45dimCD33+CD19− AML cells was likewise accompanied by outgrowth of CD45dimCD33−CD19+ cells (18% of human cells), which are presumably normal (data not shown).22 Horizontal lines represent the mean percentage engraftment of leukemic cells.

Engraftment of CD34+CLL-1+ AML blasts in NOD/SCID mice. FACS-sorted CD34+CLL-1+ cells from 3 different AML patients were transplanted into NOD/SCID mice. Six weeks after transplantation, the mice were killed and engraftment of human cells in these mice was studied using human anti-CD45. In this figure, the overall results are depicted on a logarithmic scale; every symbol represents the percentage engraftment of human CD45+ cells in one mouse. In a mouse that received a transplant of the whole CD34+ population from patient 2, which included the CD34+CD38CLL+, but also a clear CD34+CD38CLL-1 population (15% of the CD34+CD38 population), outgrowth of CD45dimCD33+CD19 AML cells was likewise accompanied by outgrowth of CD45dimCD33CD19+ cells (18% of human cells), which are presumably normal (data not shown).22  Horizontal lines represent the mean percentage engraftment of leukemic cells.

Close Modal

or Create an Account

Close Modal
Close Modal